Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines-Reference-Cited by-同舟云学术

Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines

Published:2015-12 Issue:12 Volume:34 Page:e298-e307
ISSN:0891-3668
Container-title:Pediatric Infectious Disease Journal
language:en
Short-container-title:

Author:

Vesikari Timo,Forsten Aino,Bianco Veronique,Van der Wielen Marie,Miller Jacqueline M.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Microbiology (medical),Pediatrics, Perinatology, and Child Health

Reference23 articles.

1. Global epidemiology of meningococcal disease.;Harrison;Vaccine,2009

2. Meningococcal serogroup Y emergence in Europe: update 2011.;Broker;Hum Vaccin Immunother,2012

3. The changing and dynamic epidemiology of meningococcal disease.;Halperin;Vaccine,2012

4. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.;Vesikari;Lancet,2013

5. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.;Miller;Vaccine,2001

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review;Journal of Infection;2024-09

2. Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination;Expert Review of Vaccines;2024-06-07

3. A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12–14-month-old children;Vaccine;2023-01

4. Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation;Vaccine;2022-07

5. Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial;mSphere;2022-02-23